Calendario›REGN›ALN-HSD · NASHGEN-2

ALN-HSD · NASHGEN-2

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Ensayo de REGENERON PHARMACEUTICALS, INC. en Metabolic Dysfunction-Associated SteatoHepatitis (MASH) (del registro, en inglés).

Fase

Fase 2

Estado

Reclutando pacientes

Participantes

120

previstos

Centros

71

Fin del objetivo primario

abr 2028

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en feb 2023.

Qué mide

Change in quantitative liver Fibrosis (qFibrosis) (del registro, en inglés) (del inicio a la semana 52)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making the liver inflamed and stiff from fibrosis (scar tissue). MASH can progress to cirrhosis (long term scarring) and liver failure (when the liver cannot perform its job). The aim of the study is to see the effect of the study drug on lessening liver scarring related to MASH. The study is looking at several other research questions, including: * How ALN-HSD works to improve liver function and lessen MASH-related inflammation in the liver * What side effects may happen from receiving the study drug * How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in the blood at different times * Better understanding of the study drug and MASH

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05519475), actualizada en sep 2026.